Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach
|
|
- Candace Sherman
- 6 years ago
- Views:
Transcription
1 Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA) and the European Association f the Study of Diabetes (EASD) Diabetes Care 2015;38: Diabetologia 2015;58:
2 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, 2015 Writing Group American Diabetes Association Richard M. Bergenstal MD Int l Diabetes Center, Minneapolis, MN John B. Buse MD, PhD University of Nth Carolina, Chapel Hill, NC Anne L. Peters MD Univ. of Southern Califnia, Los Angeles, CA Richard Wender MD Thomas Jefferson University, Philadelphia, PA Silvio E. Inzucchi MD (co-chair) Yale University, New Haven, CT European Assoc. f the Study of Diabetes Michaela Diamant MD, PhD (posthumous) VU University, Amsterdam, The Netherlands Ele Ferrannini MD University of Pisa, Pisa, Italy Michael Nauck MD Diabeteszentrum, Bad Lauterberg, Germany Apostolos Tsapas MD, PhD Aristotle University, Thessaloniki, Greece David R. Matthews MD, DPhil (co-chair) Oxfd University, Oxfd, UK Diabetes Care 2015;38: ; Diabetologia 2015;58:
3 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, PATIENT-CENTERED CARE 2. BACKGROUND Epidemiology and health care impact Relationship of glycemic control to outcomes Overview of the pathogenesis of Type 2 diabetes 3. ANTI-HYPERGLYCEMIC THERAPY Glycemic targets Therapeutic options - Lifestyle - Oral agents & non-insulin injectables - Insulin Diabetes Care 2012;35: ; Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
4 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, ANTIHYPERGLYCEMIC THERAPY Implementation Strategies - Initial drug therapy - Advancing to dual combination therapy - Advancing to triple combination therapy - Transitions to and titrations of insulin 4. OTHER CONSIDERATIONS Age Weight Sex/racial/ethnic/genetic differences Combidities (CAD, HF, CKD, Liver disease, Hypoglycemia-prone) 5. FUTURE DIRECTIONS / RESEARCH NEEDS Diabetes Care 2012;35: ; Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
5 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, Patient-Centered Approach...providing care that is respectful of and responsive to individual patient preferences, needs, and values - ensuring that patient values guide all clinical decisions. Gauge patient s preferred level of involvement. Exple, where possible, therapeutic choices. Consider using decision aids. Shared Decision Making a collabative process between patient and clinician, using best available evidence and taking into account the patient s preferences and values Final decisions regarding lifestyle choices ultimately lie with the patient. Diabetes Care 2012;35: ; Diabetologia 2012;55:
6 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, BACKGROUND Relationship of glycemic control to microvascular and macrovascular outcomes. Diabetes Care 2012;35: ; Diabetologia 2012;55:
7 Impact of Intensive Therapy f Diabetes: Summary of Maj Clinical Trials Study Microvasc CVD Mtality UKPDS DCCT / EDIC* ACCORD ADVANCE VADT Kendall DM, Bergenstal RM. International Diabetes Center 2009 UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854. Holman RR et al. N Engl J Med. 2008;359:1577. DCCT Research Group. N Engl J Med 1993;329;977. Nathan DM et al. N Engl J Med. 2005;353:2643. Gerstein HC et al. N Engl J Med. 2008;358:2545. Patel A et al. N Engl J Med 2008;358:2560. Duckwth W et al. N Engl J Med 2009;360:129. (erratum: Mitz T. N Engl J Med 2009;361:1024) Initial Trial Long Term Fol-up * in T1DM
8 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, BACKGROUND Overview of the pathogenesis of T2DM - Insulin secrety dysfunction - Insulin resistance (muscle, fat, liver) - Increased endogenous glucose production - Decreased incretin effect - Deranged adipocyte biology Diabetes Care 2012;35: ; Diabetologia 2012;55:
9 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption _ pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA _? hepatic glucose production renal glucose excretion peripheral glucose uptake Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine 2011
10 Multiple, Complex Pathophysiological Abnmalities in T2DM GLP-1R agonists Insulin Glinides S U s incretin effect DPP-4 inhibits Amylin mimetics _ AGIs gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion DA? agonists HYPERGLYCEMIA Metfmin _ Bile acid sequestrants hepatic glucose production renal glucose excretion s peripheral glucose uptake Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine 2011
11 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, ANTI-HYPERGLYCEMIC THERAPY Glycemic targets - HbA1c < 7.0% (mean PG mg/dl [ mmol/l]) - Pre-prandial PG <130 mg/dl (7.2 mmol/l) - Post-prandial PG <180 mg/dl (10.0 mmol/l) - Individualization is key: Tighter targets ( %) - younger, healthier Looser targets ( % ) - older, combidities, hypoglycemia prone, etc. - Avoidance of hypoglycemia PG = plasma glucose Diabetes Care 2012;35: ; Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
12 Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM PATIENT / DISEASE FEATURES Risks potentially associated with hypoglycemia and other drug adverse effects me stringent Approach to the management of hyperglycemia HbA1c 7% less stringent Disease duration newly diagnosed long-standing Life expectancy long sht Usually not modifiable Imptant combidities absent few / mild severe Established vascular complications absent few / mild severe Patient attitude and expected treatment effts ly motivated, adherent, excellent self-care capacities less motivated, non-adherent, po self-care capacities Potentially modifiable Resources and suppt system Readily available limited Diabetes Care 2015;38: ; Diabetologia 2015;58:
13 Approach to the Management of Hyperglycemia Risks potentially associated with hypoglycemia, other drug adverse effects me stringent Low Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM HbA1c 7% less stringent High Diabetes Care 2012;35: Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
14 Approach to the Management of Hyperglycemia me stringent Disease duration Newly diagnosed Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM HbA1c 7% less stringent Long-standing Diabetes Care 2012;35: Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
15 Approach to the Management of Hyperglycemia me stringent Life expectancy Long Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM HbA1c 7% less stringent Sht Diabetes Care 2015;38: ; Diabetologia 2015;58:
16 Approach to the Management of Hyperglycemia me stringent Imptant combidities Absent Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM HbA1c 7% Few / Mild less stringent Severe Diabetes Care 2015;38: ; Diabetologia 2015;58:
17 Approach to the Management of Hyperglycemia me stringent Established vascular complications Absent Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM HbA1c 7% Few / Mild less stringent Severe Diabetes Care 2015;38: ; Diabetologia 2015;58:
18 Approach to the Management of Hyperglycemia me stringent Patient attitude & expected treatment effts HbA1c 7% Highly motivated, adherent, excellent self-care capacities less stringent Less motivated, non-adherent, po self-care capacities P O T E N T I A L LY MODIFIABLE Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM Diabetes Care 2015;38: ; Diabetologia 2015;58:
19 Approach to the Management of Hyperglycemia me stringent Resources and suppt systems HbA1c 7% Readily available less stringent Limited P O T E N T I A L LY MODIFIABLE Figure 1. Modulation of the intensiveness of glucose ering therapy in T2DM Diabetes Care 2015;38: ; Diabetologia 2015;58:
20 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, ANTI-HYPERGLYCEMIC THERAPY Therapeutic options: Lifestyle - Weight optimization - Healthy diet - Increased activity level Diabetes Care 2012;35: ; Diabetologia 2012;55:
21 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, ANTI-HYPERGLYCEMIC THERAPY Therapeutic options: Oral agents & non-insulin injectables - Metfmin - Sulfonylureas - Thiazolidinediones - DPP-4 inhibits - SGLT-2 inhibits - Meglitinides - -glucosidase inhibits - Colesevelam - Dopamine-2 agonists - Amylin mimetics - GLP-1 recept agonists Diabetes Care 2012;35: ; Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
22 Oral Class Mechanism Advantages Disadvantages Cost Biguanides Sulfonylureas Meglitinides 015;38: ; Activates AMPkinase (?other) Hepatic glucose production Closes K ATP channels Insulin secretion Closes K ATP channels Insulin secretion Extensive experience No hypoglycemia Weight neutral? CVD Extensive experience Microvascular risk Postprandial glucose Dosing flexibility Gastrointestinal Lactic acidosis (rare) B-12 deficiency Contraindications Hypoglycemia Weight Low durability? Blunts ischemic preconditioning Hypoglycemia Weight? Blunts ischemic preconditioning Dosing frequency Low Low Mod. s PPAR- activat Insulin sensitivity No hypoglycemia Durability TGs (pio) HDL-C? CVD events (pio) Weight Edema/heart failure Bone fractures LDL-C (rosi)? MI (rosi) Low Table 1. Properties of anti-hyperglycemic agents Diabetes Care 2015;38: ; Diabetologia 2015;58:
23 Oral Class Mechanism Advantages Disadvantages Cost -Glucosidase inhibits DPP-4 inhibits Bile acid sequestrants Dopamine-2 agonists SGLT2 inhibits Inhibits -glucosidase Ss carbohydrate digestion / absption Inhibits DPP-4 Increases incretin (GLP-1, GIP) levels Bind bile acids? Hepatic glucose production Activates DA recept Alters hypothalamic control of metabolism insulin sensitivity Inhibits SGLT2 in proximal nephron Increases glucosuria No hypoglycemia Nonsystemic Postprandial glucose? CVD events No hypoglycemia Well tolerated No hypoglycemia LDL-C No hypoglyemia? CVD events Weight No hypoglycemia BP Effective at all stages Gastrointestinal Dosing frequency Modest A1c Angioedema / urticaria? Pancreatitis? Heart failure Gastrointestinal Modest A1c Dosing frequency Modest A1c Dizziness, fatigue Nausea Rhinitis GU infections Polyuria Volume depletion LDL-C Cr (transient) Mod. High High High High Table 1. Properties of anti-hyperglycemic agents Diabetes Care 2015;38: ; Diabetologia 2015;58:
24 Injectabl e Class Amylin mimetics GLP-1 recept agonists Insulin Mechanism Advantages Disadvantages Cost Activates amylin recept glucagon gastric emptying satiety Activates GLP-1 R Insulin, glucagon gastric emptying satiety Activates insulin recept Myriad Weight Postprandial glucose Weight No hypoglycemia Postprandial glucose Some CV risk facts Universally effective Unlimited efficacy Microvascular risk Table 1. Properties of anti-hyperglycemic agents Gastrointestinal Modest A1c Injectable Hypo if insulin dose not reduced Dosing frequency Training requirements Gastrointestinal? Pancreatitis Heart rate Medullary ca (rodents) Injectable Training requirements Hypoglycemia Weight? Mitogenicity Injectable Patient reluctance Training requirements High High Variable Diabetes Care 2015;38: ; Diabetologia 2015;58:
25 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Metfmin Figure 2. Anti-hyperglycemic therapy Basal Insulin Mealtime Insulin in T2DM: General recommendations Diabetes Care 2015;38: ; Diabetologia 2015;58:
26 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Metfmin Figure 2. Anti-hyperglycemic therapy Basal Insulin Mealtime Insulin in T2DM: General recommendations Diabetes Care 2015;38: ; Diabetologia 2015;58:
27 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Metfmin Figure 2. Anti-hyperglycemic therapy Basal Insulin Mealtime Insulin in T2DM: General recommendations Diabetes Care 2015;38: ; Diabetologia 2015;58:
28 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Basal Insulin Metfmin Mealtime Insulin Diabetes Care 2015;38: ; Diabetologia 2015;58:
29 Monotherapy Efficacy * Hypo risk Weight Side effects Metfmin Costs intolerance contraindication HbA1c 9% Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) Uncontrolled hyperglycemia (catabolic features, BG mg/dl, HbA1c 10-12%) Combination injectable therapy Basal Insulin If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Metfmin Mealtime Insulin Diabetes Care 2015;38: ; Diabetologia 2015;58:
30 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Metfmin Figure 2A. Anti-hyperglycemic Combination therapy injectable in T2DM: Basal Insulin Mealtime Insulin Avoidance therapy of hypoglycemia Diabetes Care 2015;38: ; Diabetologia 2015;58:
31 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) Figure 2B. Anti-hyperglycemic Combination therapy injectable in T2DM: Avoidance therapy of weight If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Basal Insulin Metfmin Mealtime Insulin Diabetes Care 2015;38: ; Diabetologia 2015;58:
32 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin neutral/loss GI / lactic acidosis If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea moderate risk hypoglycemia Metfmin Thiazolidinedione edema, HF, fxs Metfmin DPP-4 inhibit intermediate neutral rare Metfmin SGLT2 inhibit intermediate loss GU, dehydration Metfmin GLP-1 recept agonist loss GI Metfmin Insulin (basal) est risk hypoglycemia variable Triple therapy Metfmin Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Metfmin DPP-4 Inhibit Metfmin SGLT-2 Inhibit Metfmin GLP-1 recept agonist Metfmin Insulin (basal) If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add mealtime insulin. In refracty patients consider adding SGL T2-i: Metfmin Figure 2C. Anti-hyperglycemic Combination therapy injectable in T2DM: Basal Insulin Mealtime Insulin Minimization therapy of costs Diabetes Care 2015;38: ; Diabetologia 2015;58:
33 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, ANTI-HYPERGLYCEMIC THERAPY Therapeutic options: Insulins Human Insulins - Neutral protamine Hagedn (NPH) - Regular human insulin - Pre-mixed fmulations Insulin Analogues - Basal analogues (glargine, detemir, degludec) - Rapid analogues (lispro, aspart, glulisine) - Pre-mixed fmulations Diabetes Care 2012;35: ; Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
34 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, ANTI-HYPERGLYCEMIC THERAPY Therapeutic options: Insulins Rapid (Lispro, Aspart, Glulisine) Insulin level Sht (Regular) Long (Detemir) Long (Glargine) (Degludec) Hours Hours after injection
35 Figure 3. Approach to starting & adjusting insulin in T2DM Basal Insulin (usually with metfmin /- other non-insulin agent) Start: 10U/day U/kg/day Adjust: 10-15% 2-4 U once-twice weekly to reach FBG target. F hypo: Determine & address cause; dose by 4 units 10-20%. Diabetes Care 2015;38: ; Diabetologia 2015;58:
36 Figure 3. Approach to starting & adjusting insulin in T2DM Basal Insulin (usually with metfmin /- other non-insulin agent) Start: 10U/day U/kg/day Adjust: 10-15% 2-4 U once-twice weekly to reach FBG target. F hypo: Determine & address cause; dose by 4 units 10-20%. Add 1 rapid insulin* injections befe largest meal If not controlled after FBG target is reached ( if dose > 0.5 U/kg/day), treat PPG excursions with meal-time insulin. (Consider initial trial.) Change to premixed insulin* twice daily Start: 4U, 0.1 U/kg, 10% basal dose. If A1c<8%, consider basal by same amount. Adjust: dose by 1-2 U 10-15% oncetwice weekly until SMBG target reached. F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20%. Start: Divide current basal dose into 2/3 AM, 1/3 PM 1/2 AM, 1/2 PM. Adjust: dose by 1-2 U 10-15% oncetwice weekly until SMBG target reached. F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20%. If not controlled, consider basalbolus. Add 2 rapid insulin* injections befe meals ('basal-bolus ) Start: 4U, 0.1 U/kg, 10% basal dose/meal. If A1c<8%, consider basal by same amount. Adjust: dose by 1-2 U 10-15% once-twice weekly to achieve SMBG target. F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20%. If not controlled, consider basalbolus. Diabetes Care 2015;38: ; Diabetologia 2015;58:
37 Figure 3. Approach to starting & adjusting insulin in T2DM # Injections 1 Basal Insulin (usually with metfmin /- other non-insulin agent) Start: 10U/day U/kg/day Adjust: 10-15% 2-4 U once-twice weekly to reach FBG target. F hypo: Determine & address cause; dose by 4 units 10-20%. Complexity 2 Add 1 rapid insulin* injections befe largest meal If not controlled after FBG target is reached ( if dose > 0.5 U/kg/day), treat PPG excursions with meal-time insulin. (Consider initial trial.) Change to premixed insulin* twice daily mod. Start: 4U, 0.1 U/kg, 10% basal dose. If A1c<8%, consider basal by same amount. Start: Divide current basal dose into 2/3 AM, 1/3 PM 1/2 AM, 1/2 PM. Adjust: dose by 1-2 U 10-15% oncetwice weekly until SMBG target reached. Adjust: dose by 1-2 U 10-15% oncetwice weekly until SMBG target reached. F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20%. F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20%. 3 If not controlled, consider basalbolus. Add 2 rapid insulin* injections befe meals ('basal-bolus ) If not controlled, consider basalbolus. Start: 4U, 0.1 U/kg, 10% basal dose/meal. If A1c<8%, consider basal by same amount. Adjust: dose by 1-2 U 10-15% once-twice weekly to achieve SMBG target. F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20%. Diabetes Care 2015;38: ; Diabetologia 2015;58: Flexibility me flexible less flexible
38 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, OTHER CONSIDERATIONS Age Weight Sex / racial / ethnic / genetic differences Combidities - Conary artery disease - Heart Failure - Chronic kidney disease - Liver dysfunction - Hypoglycemia-prone Diabetes Care 2012;35: ; Diabetologia 2012;55:
39 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, FUTURE DIRECTIONS / RESEARCH NEEDS Comparative effectiveness research Focus on imptant clinical outcomes Contributions of genomic research Perpetual need f clinical judgment! Diabetes Care 2012;35: ; Diabetologia 2012;55:
40 ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, 2015 KEY POINTS Glycemic targets & BG-ering therapies must be individualized, based on a variety of patient and disease characteristics. Diet, exercise, & education: foundation of any T2DM therapy program. Unless contraindicated, metfmin remains the optimal first-line drug. After metfmin, data are limited. Combination therapy with 1-2 other al / injectable agents is reasonable. Try to minimize side effects. Ultimately, many patients will require insulin therapy alone in combination with other agents to maintain BG control. All treatment decisions should be made in conjunction with the patient (focusing on his her preferences, needs & values.) Comprehensive CV risk reduction - a maj focus of therapy. Diabetes Care 2012;35: ; Diabetologia 2012;55: Diabetes Care 2015;38: ; Diabetologia 2015;58:
Pathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationManagement of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS
Management of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationSilvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine
Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES
More informationTreating Diabetes To Lower Cardiovascular Disease Risk
Treating Diabetes To Lower Cardiovascular Disease Risk Anne Peters, MD Profess, USC Keck School of Medicine Direct, USC Clinical Diabetes Programs Disclosure of Financial Relationships 2015 Consultantship
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationInsulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationDiabetes: Inpatient Glucose control
Diabetes: Inpatient Glucose control Leanne Current, PharmD, BCPS This activity is funded through the Medicaid section 1115(a) Demonstration Texas Healthcare Transformation and Quality Improvement Program
More informationCurrent Clinical Practice Guideline for Diabetes Management
Current Clinical Practice Guideline for Diabetes Management Chaicharn Deerochanawong M.D. Professor of Medicine, i Rangsit Medical University it Diabetes and Endocrinology Unit Department of Medicine Rajavithi
More informationSGLT2 Inhibition in T2DM Management: Current Position and Future Promise
SGLT2 Inhibition, Diabetes and CVD: Where Does This Fit in CV Risk Management? ESC Congress, Rome, Italy 28 August, 2016 SGLT2 Inhibition in T2DM Management: Current Position and Future Promise Silvio
More informationLecture title. Name Family name Country
Lecture title Name Family name Country Patricia B. Gatbonton, MD, FPCP, FPSEM Endocrinology, Diabetes & Metabolism When insulin is NOT an option Learning Objectives Define factors leading to uncontrolled
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationADA/EASD Guidelines. Simon Heller. University of Sheffield
ADA/EASD Guidelines Simon Heller University of Sheffield Presenter Disclosure Advisy Board Member: Eli Lilly, NovoNdisk, Sanofi Aven
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationG lycemic management in type 2 diabetes
R e v i e w s / C o n s e n s u s R e p o r t s / A D A S t a t e m e n t s P O S I T I O N S T A T E M E N T Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Position Statement
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationAchieving Glycemic Control: When Optimized Basal Insulin Isn t Adequate
Achieving Glycemic Control: When Optimized Basal Insulin Isn t Adequate AAFP State Chapter Meeting Faculty Louis Kuritzky MD Clinical Assistant Profess Emeritus Department of Community Health and Family
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationFaculty Mark W. Stolar, MD
Disclaimer This slide deck in its iginal and unaltered fmat is f educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of the auths/presenters
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationIndiana Medicaid Drug Utilization Review Board Newsletter
Indiana Medicaid Drug Utilization Review Board Newsletter Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South Introduction The Management of Type 2 Diabetes Deborah K. Brokaw, Pharm.D.,
More informationInsulin and Oral Antidiabetic Drugs Including SGLT2 Inhibitors
Insulin and Oral Antidiabetic Drugs Including SGLT2 Inhibits S. S E THU K. R E D DY, M D, M B A, F R C P C, FAC P, M AC E PAST-CHIEF O F ADULT D I ABETES, J OSLIN D I ABETES C E N TER PAST-CHAIR O F ENDOCRINOLO
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationA Blueprint for Optimizing Diabetes Management: Implementing Guidelines in Practice
1 Disclaimer This slide deck in its iginal and unaltered fmat is f educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of the
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationNo disclosures. Diabetes Test Topics. Case #1. Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan
Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan No disclosures Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March
More informationOlder Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC
Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationDiabetes Mellitus: Overview and Guidelines
Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationHow to Use the ADA Type 2 Diabetes Treatment Algorithm. Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP
How to Use the ADA Type 2 Diabetes Treatment Algorithm Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP 8 ACOFP 55th Annual Convention & Scientific Seminars ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationEnrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School
New Diabetes Treatments Embryonic Stem Cells (ESC) Ectoderm Mesoderm Enrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School ESC Endoderm Pancreas Islet
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More information9/29/14. Disclosures. Nothing to disclose
Disclosures Nothing to disclose 1 Pharmacist Objectives 1. Select individualized glucose goals for patients with type 2 diabetes 2. List advantages and disadvantages of various classes of medications used
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationMaking Sense of Mediations for Diabetes
Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationLEADER and EMPA-REG. John Buse, MD, PhD. University of North Carolina School of Medicine Chapel Hill, NC, USA. Duality of Interest Declaration
1 LEADER and EMPA-REG John Buse, MD, PhD University of Nth Carolina School of Medicine Chapel Hill, NC, USA Duality of Interest Declaration I rept the following potential duality/dualities of interest
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More information